These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 12394845)

  • 1. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
    Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
    Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
    Zilz ND; Olson LJ; McGregor CG
    J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoma--a single-center experience of 500 liver transplantations.
    Norin S; Kimby E; Ericzon BG; Christensson B; Sander B; Söderdahl G; Hägglund H
    Med Oncol; 2004; 21(3):273-84. PubMed ID: 15456956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
    Muzaffar M; Taj A; Ratnam S
    Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
    González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
    Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.